The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection

Elion, Richard; Kaul, Sanjeev; Knupp, Catherine A.; Adler, Myra; Cross, Anne; Dunkle, Lisa M.; Kelleher, Thomas

doi:10.1016/s0149-2918(00)86733-8

Clinical Therapeutics

1999

DOI: 10.1016/s0149-2918(00)86733-8

|View full text |Cite

The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection

Richard Elion

Sanjeev Kaul

Catherine A. Knupp

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1999

2005

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nelfinavir, another currently available PI, has been used successfully in combination with nucleoside reverse transcriptase inhibitors (NRTIs), non-NRTIs and other PIs with a low incidence of adverse effects [10,11].…”

mentioning

confidence: 99%

Trimethoprim-Sulfamethoxazole (Tmp/Smx) Potentiates Indinavir Nephrotoxicity

Araújo

Seguro

2002

Antiviral Therapy

View full text Add to dashboard Cite

Objectives Indinavir is a widely prescribed protease inhibitor in the treatment of HIV infection. It has been associated with nephrolithiasis, crystalluria and tubulointerstitial nephritis. Nelfinavir is another protease inhibitor used successfully in AIDS treatment. The objective of this study was to evaluate the effect of both indinavir and nelfinavir individually, and in association with trimethoprim-sulfamethoxazole (TMP/SMX), on renal function in Wistar rats. Methods Doses of indinavir (80 mg/kg body weight [BW] daily), nelfinavir (75 mg/kg BW daily) and TMP/SMX (100 mg TMP/kg BW daily) were given by gavage for 15 days. Seven groups were studied: control, vehicle, TMP/SMX, indinavir, indinavir+TMP/SMX, nelfinavir, and nelfinavir+TMP/SMX. Results No changes were observed in body weight, urine volume and blood pressure. The vehicle group did not differ from the control group. TMP/SMX induced a small decrease in inulin clearance with no tubular alterations. Indinavir decreased inulin clearance (indinavir: 0.48 ±0.03 vs control: 0.93 ±0.08, P<0.001) and renal blood flow (indinavir: 6.2 ±0.2 vs control: 8.0 ±0.3, P<0.05). These effects were potentiated by TMP/SMX, which produced high vasoconstriction associated with alterations in tubular functions, characterised by increased fractional excretion of sodium (indinavir+TMP/SMX: 1.14 ±0.16 vs control: 0.39 ±0.07, P<0.01). Nelfinavir either alone or in combination with TMP/SMX did not change the renal function of the rats. Conclusion These results suggest that indinavir nephrotoxicity in rats is potentiated by TMP/SMX and that nelfinavir alone or in combination with TMP/SMX is not nephrotoxic.

show abstract

mentioning

confidence: 99%

Trimethoprim-Sulfamethoxazole (Tmp/Smx) Potentiates Indinavir Nephrotoxicity

Araújo

Seguro

2002

Antiviral Therapy

View full text Add to dashboard Cite

show abstract

TDM: Therapeutic Drug Measuring or Therapeutic Drug Monitoring?

Droste

Koopmans²,

Burger³

2005

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

The third round of the International Interlaboratory Quality Control Program for Therapeutic Drug Monitoring in HIV infection (QC-program) consisted of the analysis not only of plasma samples but also of patient cases. The case was composed of different topics related to the therapeutic drug monitoring of antiretroviral drugs. The participants were asked to give recommendations concerning dose adjustments, changes to the regimen, and drug-drug interactions to observe whether the expert recommendations were comparable. Of the 30 participants of the QC-program, 16 returned their comments and recommendations with regard to the patient case. The drug level was easy to judge: approximately 90% were able to correctly do so. Almost half of the recommendations (44%) given were satisfactory. Levels of knowledge regarding HIV treatment appeared to be variable among the respondents and for this reason were partly incomparable.

show abstract

Nelfinavir

Jarvis¹,

Faulds²

1998

Drugs

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection

Cited by 4 publications

References 8 publications

Trimethoprim-Sulfamethoxazole (Tmp/Smx) Potentiates Indinavir Nephrotoxicity

Trimethoprim-Sulfamethoxazole (Tmp/Smx) Potentiates Indinavir Nephrotoxicity

TDM: Therapeutic Drug Measuring or Therapeutic Drug Monitoring?

Nelfinavir

Contact Info

Product

Resources

About